Proton Pump Inhibitors versus Histamine-2 Receptor Antagonists and Risk of Pneumonia in Patients with Acute Stroke
Background Pneumonia is a serious complication of stroke. Several studies have indicated that certain gastric acid suppressants may be associated with an increased risk of pneumonia in hospitalized patients. However, the association between type of acid suppressant and pneumonia in acute stroke pati...
Gespeichert in:
Veröffentlicht in: | Journal of stroke and cerebrovascular diseases 2016-05, Vol.25 (5), p.1035-1040 |
---|---|
Hauptverfasser: | , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 1040 |
---|---|
container_issue | 5 |
container_start_page | 1035 |
container_title | Journal of stroke and cerebrovascular diseases |
container_volume | 25 |
creator | Momosaki, Ryo, MD, PhD, MPH Yasunaga, Hideo, MD, PhD Matsui, Hiroki, PT, MPH Fushimi, Kiyohide, MD, PhD Abo, Masahiro, MD, PhD |
description | Background Pneumonia is a serious complication of stroke. Several studies have indicated that certain gastric acid suppressants may be associated with an increased risk of pneumonia in hospitalized patients. However, the association between type of acid suppressant and pneumonia in acute stroke patients remains controversial. The purpose of this study was to clarify the association between the type of acid suppressant and the occurrence of pneumonia in acute stroke patients. Methods This retrospective observational study used data from the national Japanese Diagnosis Procedure Combination inpatient database. We identified patients who were admitted to acute-care hospitals with stroke. The outcome was the occurrence of pneumonia assessed using diagnostic codes. We performed propensity score-matched analysis to compare the outcome between proton pump inhibitor (PPI) users and histamine-2 receptor antagonist (H2RA) users. Results A total of 77,890 stroke patients were identified, of whom 63,980 were prescribed H2RAs and 13,910 were prescribed PPIs. Overall, 1490 (10.7%) of the patients receiving PPIs and 6401 (10.0%) of the patients receiving H2RAs developed pneumonia after stroke. After propensity score matching, the incidence of pneumonia in PPI users was not different from that in H2RA users (odds ratio: 1.10, 95% confidence interval: .99-1.21). Conclusion No significant difference in the incidence of pneumonia was seen between users of PPIs and H2RAs after acute stroke. |
doi_str_mv | 10.1016/j.jstrokecerebrovasdis.2016.01.018 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1783915069</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S1052305716000318</els_id><sourcerecordid>1783915069</sourcerecordid><originalsourceid>FETCH-LOGICAL-c459t-dc676aea1093de8d2e6f4a2c15b088377f24855af949da56c3fb92c5f78db2a43</originalsourceid><addsrcrecordid>eNqVklGL1DAUhYso7rr6FySPInRM0qZNX4RxWd2FAYddfQ5pcuum0yZjbjqy_96Ms_ogvggXEnIP59x83KJ4y-iKUda8G1cjphh2YCBCH8NBo3W44rm3oiyXfFKcM1HxUgrGnuY7FbysqGjPiheII6WMCSmeF2e8kaJiNT8v4jaGFDzZLvOe3Ph717sUIpIDRFyQXDtMenYeSk5uc-4-N8naJ_0t-NxCor0ltw53JAxk62GZ87smLhvq5MBnxQ-X7snaLAnI3a_pXxbPBj0hvHo8L4qvH6--XF6Xm8-fbi7Xm9LUokulNU3baNCMdpUFaTk0Q625YaKnUlZtO_BaCqGHru6sFo2phr7jRgyttD3XdXVRvDn57mP4vgAmNTs0ME3aQ1hQsVZWHRO06bL0w0lqYkCMMKh9dLOOD4pRdWSvRvUv9urIXlGWS2aT1495Sz-D_WPxG3YWbE4CyL8-OIgKTWZkwLoIJikb3P_lvf_LzkzOO6OnHTwAjmGJPvNVTCFXVN0dt-G4DKyhlFbZ4CfgB7qD</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1783915069</pqid></control><display><type>article</type><title>Proton Pump Inhibitors versus Histamine-2 Receptor Antagonists and Risk of Pneumonia in Patients with Acute Stroke</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Momosaki, Ryo, MD, PhD, MPH ; Yasunaga, Hideo, MD, PhD ; Matsui, Hiroki, PT, MPH ; Fushimi, Kiyohide, MD, PhD ; Abo, Masahiro, MD, PhD</creator><creatorcontrib>Momosaki, Ryo, MD, PhD, MPH ; Yasunaga, Hideo, MD, PhD ; Matsui, Hiroki, PT, MPH ; Fushimi, Kiyohide, MD, PhD ; Abo, Masahiro, MD, PhD</creatorcontrib><description>Background Pneumonia is a serious complication of stroke. Several studies have indicated that certain gastric acid suppressants may be associated with an increased risk of pneumonia in hospitalized patients. However, the association between type of acid suppressant and pneumonia in acute stroke patients remains controversial. The purpose of this study was to clarify the association between the type of acid suppressant and the occurrence of pneumonia in acute stroke patients. Methods This retrospective observational study used data from the national Japanese Diagnosis Procedure Combination inpatient database. We identified patients who were admitted to acute-care hospitals with stroke. The outcome was the occurrence of pneumonia assessed using diagnostic codes. We performed propensity score-matched analysis to compare the outcome between proton pump inhibitor (PPI) users and histamine-2 receptor antagonist (H2RA) users. Results A total of 77,890 stroke patients were identified, of whom 63,980 were prescribed H2RAs and 13,910 were prescribed PPIs. Overall, 1490 (10.7%) of the patients receiving PPIs and 6401 (10.0%) of the patients receiving H2RAs developed pneumonia after stroke. After propensity score matching, the incidence of pneumonia in PPI users was not different from that in H2RA users (odds ratio: 1.10, 95% confidence interval: .99-1.21). Conclusion No significant difference in the incidence of pneumonia was seen between users of PPIs and H2RAs after acute stroke.</description><identifier>ISSN: 1052-3057</identifier><identifier>EISSN: 1532-8511</identifier><identifier>DOI: 10.1016/j.jstrokecerebrovasdis.2016.01.018</identifier><identifier>PMID: 26853142</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>acute stroke ; Aged ; Aged, 80 and over ; Cardiovascular ; Chi-Square Distribution ; Comorbidity ; Databases, Factual ; Disability Evaluation ; Female ; Histamine H2 Antagonists - adverse effects ; histamine-2 receptor antagonists ; Humans ; Incidence ; Japan - epidemiology ; Logistic Models ; Male ; Middle Aged ; Neurology ; Pneumonia ; Pneumonia - diagnosis ; Pneumonia - epidemiology ; Propensity Score ; proton pump inhibitors ; Proton Pump Inhibitors - adverse effects ; Retrospective Studies ; Risk Factors ; Stroke - complications ; Stroke - diagnosis ; Stroke - epidemiology ; Stroke - therapy</subject><ispartof>Journal of stroke and cerebrovascular diseases, 2016-05, Vol.25 (5), p.1035-1040</ispartof><rights>National Stroke Association</rights><rights>2016 National Stroke Association</rights><rights>Copyright © 2016 National Stroke Association. Published by Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c459t-dc676aea1093de8d2e6f4a2c15b088377f24855af949da56c3fb92c5f78db2a43</citedby><cites>FETCH-LOGICAL-c459t-dc676aea1093de8d2e6f4a2c15b088377f24855af949da56c3fb92c5f78db2a43</cites><orcidid>0000-0003-3274-3952</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S1052305716000318$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26853142$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Momosaki, Ryo, MD, PhD, MPH</creatorcontrib><creatorcontrib>Yasunaga, Hideo, MD, PhD</creatorcontrib><creatorcontrib>Matsui, Hiroki, PT, MPH</creatorcontrib><creatorcontrib>Fushimi, Kiyohide, MD, PhD</creatorcontrib><creatorcontrib>Abo, Masahiro, MD, PhD</creatorcontrib><title>Proton Pump Inhibitors versus Histamine-2 Receptor Antagonists and Risk of Pneumonia in Patients with Acute Stroke</title><title>Journal of stroke and cerebrovascular diseases</title><addtitle>J Stroke Cerebrovasc Dis</addtitle><description>Background Pneumonia is a serious complication of stroke. Several studies have indicated that certain gastric acid suppressants may be associated with an increased risk of pneumonia in hospitalized patients. However, the association between type of acid suppressant and pneumonia in acute stroke patients remains controversial. The purpose of this study was to clarify the association between the type of acid suppressant and the occurrence of pneumonia in acute stroke patients. Methods This retrospective observational study used data from the national Japanese Diagnosis Procedure Combination inpatient database. We identified patients who were admitted to acute-care hospitals with stroke. The outcome was the occurrence of pneumonia assessed using diagnostic codes. We performed propensity score-matched analysis to compare the outcome between proton pump inhibitor (PPI) users and histamine-2 receptor antagonist (H2RA) users. Results A total of 77,890 stroke patients were identified, of whom 63,980 were prescribed H2RAs and 13,910 were prescribed PPIs. Overall, 1490 (10.7%) of the patients receiving PPIs and 6401 (10.0%) of the patients receiving H2RAs developed pneumonia after stroke. After propensity score matching, the incidence of pneumonia in PPI users was not different from that in H2RA users (odds ratio: 1.10, 95% confidence interval: .99-1.21). Conclusion No significant difference in the incidence of pneumonia was seen between users of PPIs and H2RAs after acute stroke.</description><subject>acute stroke</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Cardiovascular</subject><subject>Chi-Square Distribution</subject><subject>Comorbidity</subject><subject>Databases, Factual</subject><subject>Disability Evaluation</subject><subject>Female</subject><subject>Histamine H2 Antagonists - adverse effects</subject><subject>histamine-2 receptor antagonists</subject><subject>Humans</subject><subject>Incidence</subject><subject>Japan - epidemiology</subject><subject>Logistic Models</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Neurology</subject><subject>Pneumonia</subject><subject>Pneumonia - diagnosis</subject><subject>Pneumonia - epidemiology</subject><subject>Propensity Score</subject><subject>proton pump inhibitors</subject><subject>Proton Pump Inhibitors - adverse effects</subject><subject>Retrospective Studies</subject><subject>Risk Factors</subject><subject>Stroke - complications</subject><subject>Stroke - diagnosis</subject><subject>Stroke - epidemiology</subject><subject>Stroke - therapy</subject><issn>1052-3057</issn><issn>1532-8511</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqVklGL1DAUhYso7rr6FySPInRM0qZNX4RxWd2FAYddfQ5pcuum0yZjbjqy_96Ms_ogvggXEnIP59x83KJ4y-iKUda8G1cjphh2YCBCH8NBo3W44rm3oiyXfFKcM1HxUgrGnuY7FbysqGjPiheII6WMCSmeF2e8kaJiNT8v4jaGFDzZLvOe3Ph717sUIpIDRFyQXDtMenYeSk5uc-4-N8naJ_0t-NxCor0ltw53JAxk62GZ87smLhvq5MBnxQ-X7snaLAnI3a_pXxbPBj0hvHo8L4qvH6--XF6Xm8-fbi7Xm9LUokulNU3baNCMdpUFaTk0Q625YaKnUlZtO_BaCqGHru6sFo2phr7jRgyttD3XdXVRvDn57mP4vgAmNTs0ME3aQ1hQsVZWHRO06bL0w0lqYkCMMKh9dLOOD4pRdWSvRvUv9urIXlGWS2aT1495Sz-D_WPxG3YWbE4CyL8-OIgKTWZkwLoIJikb3P_lvf_LzkzOO6OnHTwAjmGJPvNVTCFXVN0dt-G4DKyhlFbZ4CfgB7qD</recordid><startdate>20160501</startdate><enddate>20160501</enddate><creator>Momosaki, Ryo, MD, PhD, MPH</creator><creator>Yasunaga, Hideo, MD, PhD</creator><creator>Matsui, Hiroki, PT, MPH</creator><creator>Fushimi, Kiyohide, MD, PhD</creator><creator>Abo, Masahiro, MD, PhD</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-3274-3952</orcidid></search><sort><creationdate>20160501</creationdate><title>Proton Pump Inhibitors versus Histamine-2 Receptor Antagonists and Risk of Pneumonia in Patients with Acute Stroke</title><author>Momosaki, Ryo, MD, PhD, MPH ; Yasunaga, Hideo, MD, PhD ; Matsui, Hiroki, PT, MPH ; Fushimi, Kiyohide, MD, PhD ; Abo, Masahiro, MD, PhD</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c459t-dc676aea1093de8d2e6f4a2c15b088377f24855af949da56c3fb92c5f78db2a43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>acute stroke</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Cardiovascular</topic><topic>Chi-Square Distribution</topic><topic>Comorbidity</topic><topic>Databases, Factual</topic><topic>Disability Evaluation</topic><topic>Female</topic><topic>Histamine H2 Antagonists - adverse effects</topic><topic>histamine-2 receptor antagonists</topic><topic>Humans</topic><topic>Incidence</topic><topic>Japan - epidemiology</topic><topic>Logistic Models</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Neurology</topic><topic>Pneumonia</topic><topic>Pneumonia - diagnosis</topic><topic>Pneumonia - epidemiology</topic><topic>Propensity Score</topic><topic>proton pump inhibitors</topic><topic>Proton Pump Inhibitors - adverse effects</topic><topic>Retrospective Studies</topic><topic>Risk Factors</topic><topic>Stroke - complications</topic><topic>Stroke - diagnosis</topic><topic>Stroke - epidemiology</topic><topic>Stroke - therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Momosaki, Ryo, MD, PhD, MPH</creatorcontrib><creatorcontrib>Yasunaga, Hideo, MD, PhD</creatorcontrib><creatorcontrib>Matsui, Hiroki, PT, MPH</creatorcontrib><creatorcontrib>Fushimi, Kiyohide, MD, PhD</creatorcontrib><creatorcontrib>Abo, Masahiro, MD, PhD</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of stroke and cerebrovascular diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Momosaki, Ryo, MD, PhD, MPH</au><au>Yasunaga, Hideo, MD, PhD</au><au>Matsui, Hiroki, PT, MPH</au><au>Fushimi, Kiyohide, MD, PhD</au><au>Abo, Masahiro, MD, PhD</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Proton Pump Inhibitors versus Histamine-2 Receptor Antagonists and Risk of Pneumonia in Patients with Acute Stroke</atitle><jtitle>Journal of stroke and cerebrovascular diseases</jtitle><addtitle>J Stroke Cerebrovasc Dis</addtitle><date>2016-05-01</date><risdate>2016</risdate><volume>25</volume><issue>5</issue><spage>1035</spage><epage>1040</epage><pages>1035-1040</pages><issn>1052-3057</issn><eissn>1532-8511</eissn><abstract>Background Pneumonia is a serious complication of stroke. Several studies have indicated that certain gastric acid suppressants may be associated with an increased risk of pneumonia in hospitalized patients. However, the association between type of acid suppressant and pneumonia in acute stroke patients remains controversial. The purpose of this study was to clarify the association between the type of acid suppressant and the occurrence of pneumonia in acute stroke patients. Methods This retrospective observational study used data from the national Japanese Diagnosis Procedure Combination inpatient database. We identified patients who were admitted to acute-care hospitals with stroke. The outcome was the occurrence of pneumonia assessed using diagnostic codes. We performed propensity score-matched analysis to compare the outcome between proton pump inhibitor (PPI) users and histamine-2 receptor antagonist (H2RA) users. Results A total of 77,890 stroke patients were identified, of whom 63,980 were prescribed H2RAs and 13,910 were prescribed PPIs. Overall, 1490 (10.7%) of the patients receiving PPIs and 6401 (10.0%) of the patients receiving H2RAs developed pneumonia after stroke. After propensity score matching, the incidence of pneumonia in PPI users was not different from that in H2RA users (odds ratio: 1.10, 95% confidence interval: .99-1.21). Conclusion No significant difference in the incidence of pneumonia was seen between users of PPIs and H2RAs after acute stroke.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>26853142</pmid><doi>10.1016/j.jstrokecerebrovasdis.2016.01.018</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0003-3274-3952</orcidid></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1052-3057 |
ispartof | Journal of stroke and cerebrovascular diseases, 2016-05, Vol.25 (5), p.1035-1040 |
issn | 1052-3057 1532-8511 |
language | eng |
recordid | cdi_proquest_miscellaneous_1783915069 |
source | MEDLINE; Elsevier ScienceDirect Journals |
subjects | acute stroke Aged Aged, 80 and over Cardiovascular Chi-Square Distribution Comorbidity Databases, Factual Disability Evaluation Female Histamine H2 Antagonists - adverse effects histamine-2 receptor antagonists Humans Incidence Japan - epidemiology Logistic Models Male Middle Aged Neurology Pneumonia Pneumonia - diagnosis Pneumonia - epidemiology Propensity Score proton pump inhibitors Proton Pump Inhibitors - adverse effects Retrospective Studies Risk Factors Stroke - complications Stroke - diagnosis Stroke - epidemiology Stroke - therapy |
title | Proton Pump Inhibitors versus Histamine-2 Receptor Antagonists and Risk of Pneumonia in Patients with Acute Stroke |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T14%3A36%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Proton%20Pump%20Inhibitors%20versus%20Histamine-2%20Receptor%20Antagonists%20and%20Risk%20of%20Pneumonia%20in%20Patients%20with%20Acute%20Stroke&rft.jtitle=Journal%20of%20stroke%20and%20cerebrovascular%20diseases&rft.au=Momosaki,%20Ryo,%20MD,%20PhD,%20MPH&rft.date=2016-05-01&rft.volume=25&rft.issue=5&rft.spage=1035&rft.epage=1040&rft.pages=1035-1040&rft.issn=1052-3057&rft.eissn=1532-8511&rft_id=info:doi/10.1016/j.jstrokecerebrovasdis.2016.01.018&rft_dat=%3Cproquest_cross%3E1783915069%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1783915069&rft_id=info:pmid/26853142&rft_els_id=1_s2_0_S1052305716000318&rfr_iscdi=true |